Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men

Source: https://dailynews.ascopubs.org/do/10.1200/ADN.22.200920/full/

MACE risk following ADT initiation was higher for older patients compared with younger patients. All comparisons were significant with a P value of < 0.05.

FCS medical oncologist Dr. Lucio Gordan is the lead investigator of this study utilizing data from more than 44,000 patients which demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).

KEY POINTS

  • Electronic medical records from more than 44,000 patients demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).
  • The risk of MACE is higher in older men with prostate cancer treated with ADT compared with younger men.
  • The overall MACE risk was similar at both 1 and 7 years after ADT initiation.

The risk of major adverse cardiovascular events (MACE) following the initiation of androgen deprivation therapy (ADT) in men with prostate cancer is higher for older men compared with their younger counterparts. However, the overall MACE risk at 1 year in all age groups starting ADT is 1% or less, which is much lower than previously published reports. The findings, gleaned from analyses of U.S. electronic medical records, were presented during the virtual National Comprehensive Cancer Network 2022 Annual Meeting.

1 thought on “Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men”

  1. A large retrospective VA study presented at ASCO 2020 reported increased MACE and more so with Agonists than antagonists. So I am skeptical about this EMR review data and it dose not differentiate Agonist vs antagonist; For patients with pre-existing or high risk I choose direct antagonists than agonists. Also to be noted there are increasing data that Abiratarone is associated with increase cardiovascular events.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study

Will we be replaced by AI? It seems that for radiologists, an AI system was better than the human counterpart in this study looking at prostate cancer diagnostic imaging. I doubt many of us would accept a solely computer-generated report, but this study highlights how AI may help as a supportive tool in the primary diagnostic setting. Of course, prospective validation will be needed.

Read More »

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

We know that combination PARP and antiandrogen is better than antiandrogen alone. I have wondered if we need antiancrogen on those patients. This shows that, YES, we do. The combination also was better than PARP inhibitor monotherapy in those patients carrying HRRm.

Read More »

CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

The role for immunotherapy in combination with multitargeted therapy in prostate cancer, for patients who had previous docetaxol, or had visceral disease (liver) showed more benefit from the combination vs. second novel hormonal therapy. Recall that patients who had exposure to docetaxol can be treated with pluvicto. Genomic and genetic testing is encouraged for those patients as PARP targeted mutations can be found (homologous recombination-repair mutations).

Read More »